

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-32. (Canceled)

33. (Currently amended) A method of ~~preventing or treating~~ inhibiting rejection of a grafted cell, tissue, or organ in a mammal comprising administering to the mammal a composition comprising a purified complex consisting essentially of a heat shock protein non-covalently bound to a peptide, wherein the peptide is not an alloantigen of the grafted cells, tissue, or organ, and wherein the heat shock protein is a member of the hsp90 family of heat shock proteins.

34. (Currently amended) A method of ~~preventing or treating~~ inhibiting rejection of a grafted cell, tissue, or organ in a mammal comprising administering to the mammal a composition comprising a purified complex consisting essentially of a heat shock protein non-covalently bound to a peptide, wherein the peptide is not an alloantigen of the grafted cells, tissue, or organ, and wherein the heat shock protein is a member of the hsp70 family of heat shock proteins.

35. (Previously presented) The method of claim 33 or 34, wherein the heat shock protein is not an alloantigen of the grafted cells, tissue, or organ.

36. (Previously presented) The method of claim 33 or 34, wherein the grafted cell, tissue, or organ is skin, liver, kidney, heart, bone marrow, pancreas, lung, cornea, cartilage, or a cell derived therefrom.

37. (Previously presented) The method of claim 33 or 34, wherein the grafted cell or tissue is skin or a cell derived from skin.

38. (Previously presented) The method of claim 33 or 34, wherein the heat shock protein is mammalian.

39. (Previously presented) The method of claim 33 or 34, wherein the heat shock protein is human.

40. (Previously presented) The method of claim 33, wherein the heat shock protein is gp96.
41. (Previously presented) The method of claim 33, wherein the heat shock protein is hsp90.
42. (Previously presented) The method of claim 34, wherein the heat shock protein is hsp70.
43. (Currently amended) The method of claim ~~33, 34, or 35~~ 33 or 34, wherein the mammal is human.
44. (Previously presented) The method of claim 33 or 34, comprising administering the composition before the cell, tissue, or organ is grafted.
45. (Previously presented) The method of claim 33 or 34, comprising administering the composition after the cell, tissue, or organ is grafted.
46. (Previously presented) The method of claim 33 or 34, wherein the amount of the complex present in the composition is in a range of 5 µg to 5,000 µg.
47. (Previously presented) The method of claim 33 or 34, wherein the amount of the complex present in the composition is 100 µg or more.
48. (Previously presented) The method of claim 33 or 34, wherein the amount of the complex present in the composition is 200 µg or more.
49. (Previously presented) The method of claim 33 or 34, further comprising administering to the mammal a sample of cells or tissue obtained from the cell, tissue, or organ donor prior to administration of the heat shock protein.
50. (Previously presented) The method of claim 33 or 34, wherein the peptide is not a bacterial peptide.
51. (Previously presented) The method of claim 33 or 34, wherein said composition comprises a purified population of complexes, each complex in said population consisting essentially of a heat shock protein non-covalently bound to a peptide, and wherein each peptide is independently selected from a population of different peptides.

52. (Previously presented) The method of claim 39, wherein the heat shock protein is gp96, and wherein the mammal is human.

53. (New) The method of claim 33 or 34, wherein the heat shock protein is not an alloantigen of the grafted cells, tissue, or organ, and wherein the mammal is a human.